Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making
NCT ID: NCT01607970
Last Updated: 2012-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
80 participants
INTERVENTIONAL
2011-08-31
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Oxytocin Modulation of Responses to Emotional Stimuli
NCT04320706
The Influence of Oxytocin on Pair-bonding and Emotion Regulation
NCT02501837
Effect of Oral Oxytocin on Women's Response to Emotional Stimuli
NCT05073939
Inhaled Oxytocin and HPA Axis Reactivity
NCT03593473
Oxytocin for Couples Conflict Resolution
NCT02941692
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxytocin
24 IU Oxytocin, intranasal application 45 min prior to the experiment
Oxytocin
Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
Placebo
intranasal application, sodium chloride solution, 3 puffs per nostril
Oxytocin
Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Current or past physical illness
* Psychoactive medication
* Tobacco smokers
18 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bonn
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rene Hurlemann
MSc MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rene Hurlemann, MSc MD PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Psychiatry, University of Bonn, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, University of Bonn
Bonn, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about the NEMO research group
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OXT-168/11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.